Share & Enjoy:

|

Author:
Steve Roome

Ascent Scientific (www.ascentscientific.com) announced the expansion of its Low-Cost Ligand ™ glutamate range – chemical tools that will aid research into a wide range of neurological disorders. The range includes groundbreaking research tools such as Fenobam, MTEP, and YM-298198 and will aid research into disorders such as anxiety, pain, Alzheimers, epilepsy and stress-related conditions.

Bristol, UK (PRWEB) March 30, 2006 -- Ascent Scientific expands Low-Cost Ligand™ glutamate range, to help research into neurological disorders.

Ascent Scientific (www.ascentscientific.com) announced the expansion of its Low-Cost Ligand ™ glutamate range – chemical tools that will aid research into a wide range of neurological disorders. The range includes groundbreaking research tools such as Fenobam, MTEP, and YM-298198 and will aid research into disorders such as anxiety, pain, Alzheimers, epilepsy and stress-related conditions.

Steve Roome PhD, Commercial Director commented, “Our newly expanded range includes exciting new research tools such as Fenobam, MTEP and the novel YM-298198, which is currently only available from Ascent Scientific. In addition, we have introduced a range of popular standard tools including CNQX and MK-801. The expanded Low-Cost Ligand™ glutamate range is particularly special, as the tools are offered at prices up to 50% less than other suppliers – in keeping with our philosophy to make research tools affordable for as many researchers as possible.”

About Ascent Scientific
Ascent Scientific provides high quality receptor ligands, synthetic chemistry, research, consultancy and analytical services for life science, pharmaceutical and chemistry-related industries.

The Low-Cost Ligand™ range includes glutamate, histamine, purinergic and vanilloid receptor ligands together with signalling tools. The glutamate range includes:

-   AMN082: the first selective mGlu7 agonist
-   D-AP5: Potent selective NMDA antagonist
-   L-AP4: selective group III mGlu agonist
-   CNQX: AMPA/Kainate receptor antagonist
-   Fenobam: novel mGlu5 antagonist
-   (+)-MK 801: potent, selective NMDA antagonist
-   MTEP: brain penetrant, selective mGlu5 antagonist
-   MPEP: mGlu5 selective antagonist
-   YM298198: potent, selective mGlu1 antagonist

Contact:
Steve Roome, Commercial Director +44 (0)1934 624 695

Share & Enjoy: |     Article Keywords: Epilepsy

A Quick Note From The Publisher... If you like the article above, you may be interested in the following article which is also related to Epilepsy... Epilepsy Foundations Approximately 2% of the US population suffers from epilepsy, one of the widely prevalent neurological disorders in the world. To ensure that these people lead a relatively healthy and comfortable life, a voluntary health organization called The Epilepsy Foundation exists. This organization advises, educates and provides various services to epileptics and their families. The agency is an active member of the International Bureau for Epilepsy and National Health Council. The Foundation works at the national as well as international levels through franchises and offices. Few examples are Epilepsy Foundation of New Jersey, Epilepsy Foundation of Michigan, and Epilepsy Foundation of Colorado. The primary aim is to ensure that patients take part in all activities performed by healthy person. The agency also undertakes research on possible preventive and curative methods for the disorder. It also takes effort to change legislative laws toward enabling epileptics have equal...